Skip to main content

Table 3 Comparison of HCCs showing local progression and no local progression, in nodules classified with a complete response

From: Lipiodol retention pattern after TACE for HCC is a predictor for local progression in lesions with complete response

 Local progression N = 25No local progression
N = 21
p value*
Serum AFP level (μg /L) ± SD37 ± 18122 ± 720.40
HCC size (mm) ± SD23 ± 722.6 ± 120.78
HCC location   
- Right lobe20 (80%)14 (66%)0.49
- Left Lobe5 (20%)7 (33%)
Capsule Appearance6 (24%)7 (33%)0.70
CBCT guidance15 (60%)10 (48%)0.82
Selective cTACE Treatment18 (72%)15 (71%)0.77
Mean Delivered Dose (mg) ± SD35 ± 1748 ± 230.03
Presence of gas on follow-up CT1 (4%)0 (0%)0.93
Embolization Agent
- Gelitaspon23 (92%)15 (71%)0.11
- PVA particles0 (0%)3 (14%)
- No embolization2 (8%)3 (14%)
  1. *Chi2 test and t-test were used for analysis of discrete and continuous variables respectively
  2. AFP Alpha-fetoprotein, CBCT Cone beam computed tomography, HCC Hepatocellular carcionoma, PVA Polyvinyl alcohol, SD Standard deviation, cTACE Conventional transarterial chemoembolization